Literature DB >> 624904

Modulation of the formation of the amplification convertase of complement, C3b, Bb, by native and commercial heparin.

J M Weiler, R W Yurt, D T Fearon, K F Austen.   

Abstract

Native rat mast cell macromolecular heparin proteoglycan and commercial hog heparin glycosaminoglycan chains inhibit generation of the amplification convertase, C3b, Bb. The inhibitory action of heparin is not due to chelation of magnesium. Heparin is most active in inhibiting convertase formation on cellular intermediates formed with the lowest C3b input and developed with the highest B concentration, thereby suggesting the receptor site for B on C3b as the point of heparin action. This interpretation is consistent with the demonstration that heparin prevents B utilization during the fluid phase interaction of C3b, B, and D. Inhibition is observed also when C3b,Bb generation takes place on cellular intermediates in the presence of P or C3NeF, which yield stabilized forms of the convertase. 50 times the concentration of heparin required to inhibit convertase generation does not accelerate the decay of the unstabilized or the C3NeF-stabilized convertases and has only a modest effect on the P-stabilized convertase. An additional effect of heparin is to impair beta1H-mediated decay-dissociation of C3b,Bb. The concentration of native or commercial heparin which prevents convertase formation is in the same range as that required for the demonstration of its anti-coagulant and anti-thrombin III cofactor activities. The additional finding that this inhibitory action of heparin can be expressed by the isolated mast cell granule suggests that native heparin may contribute to the modulation of the amplification pathway of complement.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 624904      PMCID: PMC2184494          DOI: 10.1084/jem.147.2.409

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  30 in total

1.  MAST CELL POPULATION IN HUMAN SKIN.

Authors:  G R MIKHAIL; A MILLER-MILINSKA
Journal:  J Invest Dermatol       Date:  1964-10       Impact factor: 8.551

2.  A modified uronic acid carbazole reaction.

Authors:  T BITTER; H M MUIR
Journal:  Anal Biochem       Date:  1962-10       Impact factor: 3.365

3.  Aliphatic ammonium salts in the assay of acidic polysaccharides from tissues.

Authors:  J E SCOTT
Journal:  Methods Biochem Anal       Date:  1960

4.  Immunologic release of heparin from purified rat peritoneal mast cells.

Authors:  R W Yurt; R W Leid; J Spragg; K F Austen
Journal:  J Immunol       Date:  1977-04       Impact factor: 5.422

5.  Antibody-independent activation of the alternative complement pathway in human serum by parasitic cells.

Authors:  F Kierszenbaum; D Weinman
Journal:  Immunology       Date:  1977-02       Impact factor: 7.397

6.  Native heparin from rat peritoneal mast cells.

Authors:  R W Yurt; R W Leid; K F Austen
Journal:  J Biol Chem       Date:  1977-01-25       Impact factor: 5.157

7.  Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms.

Authors:  D T Fearon; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1977-04       Impact factor: 11.205

8.  Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins.

Authors:  D T Fearon; K F Austen
Journal:  J Exp Med       Date:  1977-07-01       Impact factor: 14.307

9.  Studies on the mechanism of hypersensitivity phenomena. III. The participation of complement in the formation of anaphylatoxin.

Authors:  A G OSLER; H G RANDALL; B M HILL; Z OVARY
Journal:  J Exp Med       Date:  1959-08-01       Impact factor: 14.307

10.  ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT.

Authors:  U R NILSSON; H J MUELLER-EBERHARD
Journal:  J Exp Med       Date:  1965-08-01       Impact factor: 14.307

View more
  25 in total

1.  Regulation of C5 convertase activity by properdin, factors B and H.

Authors:  J M Weiler
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

2.  Effect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation.

Authors:  T E Mollnes; P Garred; G Bergseth
Journal:  Clin Exp Immunol       Date:  1988-09       Impact factor: 4.330

3.  Local Inhibition of Complement Improves Mesenchymal Stem Cell Viability and Function After Administration.

Authors:  Yan Li; John Fung; Feng Lin
Journal:  Mol Ther       Date:  2016-07-05       Impact factor: 11.454

Review 4.  Biology of the mast cell and its role in cutaneous inflammation.

Authors:  B U Wintroub; N A Soter
Journal:  Springer Semin Immunopathol       Date:  1981-06

5.  Eosinophil granule cationic proteins regulate the classical pathway of complement.

Authors:  J M Weiler; R E Edens; C S Bell; G J Gleich
Journal:  Immunology       Date:  1995-02       Impact factor: 7.397

Review 6.  Mast cells in allergic diseases and mastocytosis.

Authors:  D L Marquardt; S I Wasserman
Journal:  West J Med       Date:  1982-09

7.  Factors influencing the interaction of herpes simplex virus glycoprotein C with the third component of complement.

Authors:  H P Huemer; C Larcher; M P Dierich; D Falke
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

8.  Modulation of the formation of the human amplification C3 convertase of complement by polycations.

Authors:  F Maillet; M D Kazatchkine
Journal:  Immunology       Date:  1983-09       Impact factor: 7.397

9.  Modulation of the formation of the human C-3 amplification convertase of complement by polyelectrolytes.

Authors:  M D Kazatchkine; F Maillet; E Fischer; D Glotz
Journal:  Agents Actions       Date:  1981-12

10.  Anticomplement therapy.

Authors:  Prathit A Kulkarni; Vahid Afshar-Kharghan
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.